#ASH18: Re­gen­eron's bis­pe­cif­ic REGN1979 of­fers eye-catch­ing 80% CR rate in fol­lic­u­lar lym­phoma, spurring swift shift to piv­otal study

As one of the world’s top — and cer­tain­ly best paid — an­ti­body drug de­vel­op­ers, Re­gen­eron’s George Yan­copou­los tends to at­tract a con­sid­er­able amount of at­ten­tion when he gets ex­cit­ed by one of his clin­i­cal projects. And to­day you’ll find him ea­ger­ly tout­ing a bis­pe­cif­ic ther­a­py that the R&D chief has sky-high hopes for.

Ev­i­dent­ly with good rea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER